Breaking News Instant updates and real-time market news.

AIMT

Aimmune

$21.57

0.07 (0.33%)

10:49
03/25/19
03/25
10:49
03/25/19
10:49

Aimmune news 'de-risking' for AR101 in Europe, says Piper Jaffray

Piper Jaffray analyst Christopher Raymond says that while details were limited with the data embargoed, he views this morning's announcement from Aimmune Therapeutics as "de-risking." It provides another set of Phase 3 safety and efficacy data for AR101, Raymond tells investors in a research note. He expects more clarity in June when the data are presented, but adds that management commentary indicates efficacy and safety are in line with the Phase 3 Palisade data. Raymond continues to like the set-up for the shares and remains a buyer of Aimmune with an Overweight rating and $60 price target.

  • 25

    Mar

AIMT Aimmune
$21.57

0.07 (0.33%)

02/14/19
PIPR
02/14/19
NO CHANGE
Target $60
PIPR
Overweight
Aimmune should be bought on any weakness from NEJM letter, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond tells investors to buy shares of Aimmune Therapeutics on any weakness after a letter to the editor published in this week's New England Journal of Medicine questioned the safety of AR101. The analyst views the letter as "clearly biased" and notes it "purposely" conflates AR101 with "unrelated, and irrelevant" oral immunotherapy approaches. Moreover, a little digging shows the author of the letter has ownership interest in Prota Therapeutics, an oral immunotherapy competitor to AR101, which "should have received more consideration by NEJM reviewers in the first place," Raymond tells investors in a research note. "That this bias was seemingly ignored, allowing a clearly misleading letter such as this to be published raises what we see as serious questions regarding NEJMs editorial process," adds the analyst. As such, he views the letter as "nothing more than noise." Raymond keeps an Overweight rating on Aimmune with a $60 price target.
03/06/19
PIPR
03/06/19
NO CHANGE
PIPR
Departure of Gottlieb brings some biopharma uncertainty, says Piper Jaffray
Piper Jaffray remains "largely bullish" on the biopharma sector but acknowledges a "new and unexpected" source of uncertainty now with the announced departure of FDA commissioner Scott Gottlieb, analysts led by Christopher Raymond tell investors in a research note. With a track record of favoring innovation and pushing for increased regulatory efficiency while also advocating for more competition, Dr. Gottlieb was about as "market friendly, patient focused and industry friendly as one could have hoped," Piper writes. The firm adds that while it has no reason to believe the next commissioner "will be quite as radical and potentially damaging to the industry," it does think investors would do well to watch the selection process very closely.
03/12/19
PIPR
03/12/19
NO CHANGE
PIPR
Biopharma stocks should be up sharply on Sharpless selection, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he expects biopharma stocks to be up sharply on news that former National Cancer Institute director Ned Sharpless will be named acting FDA commissioner. The biotech sector "experienced a swoon of sorts" since Scott Gottlieb announced his departure, but with the announcement of Gottlieb's favored choice as successor Raymond believes the FDA will remain "on its current industry-friendly and efficiency driven trajectory," the analyst tells investors.
03/18/19
PIPR
03/18/19
NO CHANGE
PIPR
Overweight
Aimmune news derisking, but no expedited review, says Piper Jaffray
The FDA's acceptance of Aimmune Therapeutics' Biologics License Application for AR101 is "clearly derisking," but the standard 12-month review period is "clearly at odds" with the drug's Breakthrough Therapy and Fast Track Designation, Piper Jaffray analyst Christopher Raymond tells investors in a research note. The analyst, however, says he never modeled commercialization before Q1 of 2020, and as such views timing as in-line with his model. Further, the analyst points out that the indicated advisory committee to review the filing has long been expected and "should surprise no one." Raymond keeps an Overweight rating on Aimmune shares with a $60 price target.

TODAY'S FREE FLY STORIES

VIAC

ViacomCBS

$37.79

0.52 (1.40%)

08:36
12/13/19
12/13
08:36
12/13/19
08:36
Initiation
ViacomCBS initiated  »

ViacomCBS reinstated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLRB

Cellectar Biosciences

$2.23

0.12 (5.69%)

08:35
12/13/19
12/13
08:35
12/13/19
08:35
Hot Stocks
Cellectar Biosciences presents data on CLR 2000045 at AACR symposium »

Cellectar Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OCFT

OneConnect

$0.00

(0.00%)

08:35
12/13/19
12/13
08:35
12/13/19
08:35
Syndicate
OneConnect 31.2M share IPO priced at $10.00 »

The deal size was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ONCS

OncoSec

$2.39

-0.04 (-1.65%)

, MRK

Merck

$88.95

0.6 (0.68%)

08:34
12/13/19
12/13
08:34
12/13/19
08:34
Hot Stocks
OncoSec reports interim results from KEYNOTE-890 study »

OncoSec announced interim…

ONCS

OncoSec

$2.39

-0.04 (-1.65%)

MRK

Merck

$88.95

0.6 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

  • 24

    Jan

  • 24

    Jan

  • 05

    Feb

  • 14

    Mar

CFX

Colfax

$35.74

0.6 (1.71%)

08:34
12/13/19
12/13
08:34
12/13/19
08:34
Conference/Events
Colfax to host investor day »

Investor day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

SRPT

Sarepta

$100.39

-1.15 (-1.13%)

08:33
12/13/19
12/13
08:33
12/13/19
08:33
Hot Stocks
Sarepta announces $250M of non-dilutive senior secured loan financing »

Sarepta Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ADBE

Adobe

$305.76

2.01 (0.66%)

08:33
12/13/19
12/13
08:33
12/13/19
08:33
Recommendations
Adobe analyst commentary  »

Adobe price target raised…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

ATNX

Athenex

$16.94

-0.36 (-2.08%)

08:32
12/13/19
12/13
08:32
12/13/19
08:32
Hot Stocks
Athenex announces results from Phase III trial of oral paclitaxel »

Athenex announced results…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

PFE

Pfizer

$38.54

0.3 (0.78%)

08:32
12/13/19
12/13
08:32
12/13/19
08:32
Hot Stocks
Pfizer announces CHMP recommendation for approval of Vyndaqel »

Pfizer announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TREE

LendingTree

$293.67

-13 (-4.24%)

08:31
12/13/19
12/13
08:31
12/13/19
08:31
Recommendations
LendingTree analyst commentary  »

LendingTree price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNM

Unum Group

$31.01

0.82 (2.72%)

08:30
12/13/19
12/13
08:30
12/13/19
08:30
Conference/Events
Unum Group to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Dec

08:30
12/13/19
12/13
08:30
12/13/19
08:30
Options
One option delisting on December 13th »

Option delistings…

08:25
12/13/19
12/13
08:25
12/13/19
08:25
Conference/Events
Federal Reserve Bank of New York president participates in a discussion »

New York Federal Reserve…

FORM

FormFactor

$24.96

1.19 (5.01%)

, INTC

Intel

$57.56

0.52 (0.91%)

08:25
12/13/19
12/13
08:25
12/13/19
08:25
Recommendations
FormFactor, Intel, Samsung, TSMC analyst commentary  »

FormFactor price target…

FORM

FormFactor

$24.96

1.19 (5.01%)

INTC

Intel

$57.56

0.52 (0.91%)

SSNLF

Samsung

$0.00

(0.00%)

TSM

TSMC

$58.61

2.71 (4.85%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Dec

  • 23

    Jan

$DJT

DJ Transportation Average

$0.00

(0.00%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Technical Analysis
DJ Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$DJU

DJ Utility Average

$0.00

(0.00%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Technical Analysis
DJ Utility Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DJX

Dow Jones Industrial Average

$0.00

(0.00%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Technical Analysis
Dow Jones Industrial Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAS

Masco

$47.44

1 (2.15%)

, FBHS

Fortune Brands

$65.51

0.31 (0.48%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Recommendations
Masco, Fortune Brands analyst commentary  »

Masco, Fortune Brands…

MAS

Masco

$47.44

1 (2.15%)

FBHS

Fortune Brands

$65.51

0.31 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IYT

iShares Transportation Average

$194.19

2.09 (1.09%)

08:24
12/13/19
12/13
08:24
12/13/19
08:24
Technical Analysis
iShares Transportation Average: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLK

Technology Select Sector SPDR

$88.89

0.9 (1.02%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Technical Analysis
Technology Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLE

Energy Select Sector SPDR

$60.86

1.19 (1.99%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Technical Analysis
Energy Select Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HZNP

Horizon Pharma

$32.84

0.58 (1.80%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Conference/Events
The FDA Dermatologic & Ophthalmic Drugs Advisory Committee to hold a meeting »

The Committee discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 08

    Mar

XLY

Consumer Discretionary Sector SPDR

$123.10

1.12 (0.92%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Technical Analysis
Consumer Discretionary Sector SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLB

S&P Select Materials SPDR

$60.92

0.85 (1.42%)

08:23
12/13/19
12/13
08:23
12/13/19
08:23
Technical Analysis
S&P Select Materials SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XLU

Utilities SPDR

$62.86

-0.32 (-0.51%)

08:22
12/13/19
12/13
08:22
12/13/19
08:22
Technical Analysis
Utilities SPDR: Pivot points »

The following are the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.